A 58-year-old man is hospitalized for pyelonephritis and bacteremia. Initial blood cultures grow *Enterobacter cloacae*. Antibiotic susceptibility testing indicates that the isolate is susceptible to ceftriaxone, and therapy with this agent is initiated. The patient initially improves, but on day 5 of hospitalization, he develops recurrent fever, tachycardia, and a rising leukocyte count. Repeat blood cultures grow *Enterobacter cloacae* that is now resistant to ceftriaxone, ceftazidime, and piperacillin-tazobactam, but remains susceptible to meropenem and amikacin. Which of the following best describes the molecular mechanism responsible for the pathogen's new resistance profile?
- Derepression of a chromosomal gene encoding an enzyme that hydrolyzes the beta-lactam ringCevap
- BPlasmid-mediated acquisition of an extended-spectrum beta-lactamase
- CDownregulation of outer membrane porin channel expression
- DStructural alteration of penicillin-binding proteins via horizontal gene transfer
- EEnzymatic modification of the antibiotic via an acetyltransferase
Cevap
Derepression of a chromosomal gene encoding an enzyme that hydrolyzes the beta-lactam ring
The correct answer describes the derepression of the chromosomal AmpC beta-lactamase gene. Certain Gram-negative bacilli, often remembered by the mnemonic 'SPACE' or 'ESPM' (Enterobacter, Serratia, Pseudomonas, Morganella), harbor an inducible, chromosomal AmpC beta-lactamase gene. When these organisms are exposed to certain beta-lactam antibiotics like ceftriaxone, a mutant subpopulation that constitutively hyperproduces (derepresses) the AmpC enzyme is selected for. This results in clinical failure and widespread beta-lactam resistance, including resistance to third-generation cephalosporins and beta-lactamase inhibitors like piperacillin-tazobactam. Carbapenems, such as meropenem, are stable against AmpC hydrolysis and remain the treatment of choice for severe infections with these organisms.
Adım Adım Çözüm
Anahtar Kavram
Organisms with inducible chromosomal AmpC beta-lactamases (such as Enterobacter, Serratia, and Citrobacter) can rapidly develop resistance to third-generation cephalosporins during therapy due to derepression of the AmpC gene.